When do the JADELLE patents expire, and when will generic JADELLE be available?

Sponsor	Phase
University of Pittsburgh	Phase 2
Chulalongkorn University	Phase 4
Infectious Diseases Institute, Uganda	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Population Council	JADELLE	levonorgestrel	IMPLANT;IMPLANTATION	020544-001	Nov 1, 1996		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 17, 2026

Jadelle is a two-rod levonorgestrel contraceptive implant used primarily in public-sector family-planning programs in low- and middle-income countries. Its commercial profile is defined by procurement contracts, donor financing, regulatory approvals, and competition from etonogestrel implants and newer levonorgestrel intrauterine systems rather than by retail sales.

Standalone Jadelle revenue is not publicly disclosed. The product has limited commercial exposure in the United States and no active U.S. Orange Book growth strategy. Its value is concentrated in global health procurement, where low unit cost, five-year duration, provider familiarity, and availability through international tenders support demand.

What is Jadelle and how does it generate revenue?

Jadelle contains two flexible rods, each releasing 75 mg of levonorgestrel. The rods are inserted subdermally in the upper arm and provide contraceptive protection for up to five years under the approved labeling in many markets. The product requires a trained provider for insertion and removal, creating a service-delivery component that affects adoption and total program cost.

Attribute	Jadelle
Active ingredient	Levonorgestrel
Dosage form	Two-rod subdermal implant
Contraceptive duration	Up to five years
Primary customers	Ministries of health, UN agencies, NGOs, donor-funded programs
Commercial channel	Public tenders and reproductive-health procurement
U.S. retail presence	Limited or absent
Revenue disclosure	No standalone public revenue
Main competitors	Nexplanon/Implanon NXT, Sino-implant II, levonorgestrel intrauterine systems
Key commercial advantage	Long duration and relatively low procurement cost

Jadelle’s financial model is closer to a contracted public-health product than to a branded specialty pharmaceutical. Revenue depends on annual procurement volumes, tender wins, donor budgets, manufacturing continuity, and country registrations.

How large is the Jadelle market?

The addressable market is the global long-acting reversible contraception market, with Jadelle occupying a subsegment of contraceptive implants. Demand is strongest in sub-Saharan Africa and selected Asian and Latin American markets where ministries and donor organizations fund contraceptive access.

The broader implant market has expanded because implants provide several years of contraception without daily adherence. The expansion has been supported by the Implant Access Program, which helped lower prices and increase procurement of implants including Jadelle and Sino-implant II. The program was backed by organizations including the Bill & Melinda Gates Foundation, the UK government, USAID, and the Clinton Health Access Initiative. [1]

Jadelle does not control the implant category. Nexplanon has stronger commercial positioning in many private and higher-income markets, while Sino-implant II has competed aggressively in donor-supported procurement after obtaining World Health Organization prequalification. [2]

Key demand drivers

High unmet need for contraception. Countries with rapid population growth and low modern contraceptive prevalence remain the main demand centers.
Five-year duration. Long duration reduces repeat clinic visits and recurring product costs.
Commodity price reductions. Lower implant prices improved affordability for large public programs.
Provider infrastructure. Jadelle can be deployed where governments have trained insertion and removal providers.
Donor procurement. Global health agencies often purchase implants in large tenders, reducing dependence on commercial retail distribution.

Market constraints

Jadelle demand is constrained by the need for insertion and removal services, provider training, product availability, regulatory registration, and counseling capacity. Removal access is particularly important because women may discontinue use before the five-year term.

The product also faces competition from contraceptive methods with lower procedural requirements, including oral contraceptives, injectables, intrauterine devices, and condoms.

What is Jadelle’s financial trajectory?

Jadelle’s standalone financial trajectory cannot be calculated from public company filings because its sales are not separately reported. The available evidence supports a volume-driven, lower-price model rather than a high-margin branded-drug model.

Commercial phases

Period	Market development	Financial implication
1990s	FDA approval and early commercialization	Establishment of the product and regulatory base
2000s	Broader international access and public-sector use	Increasing dependence on non-U.S. markets
2010s	Price reductions and donor-backed implant scale-up	Higher potential volume, lower revenue per unit
2020s	Continued public-health procurement and portfolio competition	Stable demand but limited pricing power

Bayer has historically been associated with Jadelle commercialization and manufacturing arrangements, while the Population Council developed the technology and has played a central role in product access. Public communications have emphasized access in developing countries rather than premium pricing. [3]

The reduction in procurement prices improved affordability but likely reduced nominal revenue per implant set. For a five-year implant, the relevant commercial metric is not only the price per unit but also the number of procedures, removal services, stock-outs, tender renewals, and replacement cycles.

What is the procurement price for Jadelle?

Reported Jadelle pricing has varied by contract, country, shipment size, and procurement channel. In the international procurement market, the product has been sold at substantially lower prices than in early commercial periods. Public-sector implant access initiatives reported Jadelle prices near the high-single-digit dollar range per implant set during major price-reduction programs. [1]

A procurement price near $8 to $10 per five-year implant does not equal total treatment cost. Programs also incur costs for:

Provider training
Insertion and removal equipment
Counseling
Logistics and inventory
Adverse-event management
Demand generation
Follow-up services

Even after adding service costs, a long-acting implant can have a favorable cost per couple-year of protection compared with methods requiring frequent resupply. The economic benefit depends on continuation, timely removals, and adequate clinic capacity.

How does Jadelle compare with Nexplanon and Sino-implant II?

Jadelle competes on price, duration, regulatory status, provider familiarity, and procurement eligibility.

Product	Hormone	Implant design	Typical duration	Commercial positioning
Jadelle	Levonorgestrel	Two rods	Five years	Public-sector and donor procurement
Nexplanon/Implanon NXT	Etonogestrel	One rod	Up to three years in original labeling, with evidence supporting longer use in some settings	Branded global and private-sector product
Sino-implant II	Levonorgestrel	Two rods	Four years under original labeling	Lower-cost public-sector competitor
Levoplant	Levonorgestrel	Two rods	Three years	Lower-cost procurement alternative

Nexplanon has an insertion advantage because it uses a single rod and is supplied with an insertion device. Jadelle’s two-rod design may require more insertion training, although it is familiar in many public programs.

Sino-implant II competes most directly with Jadelle because both use levonorgestrel and a two-rod configuration. WHO prequalification and country registrations influence whether a product is eligible for procurement by international agencies. [2]

What FDA and Orange Book status applies to Jadelle?

Jadelle received U.S. FDA approval in 1996 under NDA 020544. It is not a major current U.S. commercial product, and its market significance is international rather than U.S.-retail based. FDA approval does not establish meaningful current U.S. sales.

Jadelle is not a conventional Orange Book-driven generic-entry opportunity. The principal commercial markets are outside the U.S., and procurement access depends on local registrations, WHO-related eligibility, tender rules, and supply arrangements.

The product’s U.S. regulatory history is relevant to technical validation but does not provide a reliable indicator of current global revenue. No current blockbuster-style U.S. exclusivity period should be assigned to Jadelle.

When did Jadelle lose exclusivity?

Jadelle’s original U.S. regulatory and patent exclusivity periods expired long ago relative to the current market. The product is based on an established active ingredient, and the relevant commercial barriers are no longer conventional composition-of-matter exclusivity.

Current protection is more likely to involve:

Country-specific registrations
Manufacturing know-how
Device and applicator design
Process controls
Quality systems
Trademarks
Regulatory dossiers
Supplier qualification
Procurement relationships

Publicly available information does not support a current, material global patent barrier that would prevent technically capable manufacturers from developing a levonorgestrel implant. The more important barriers are clinical validation, manufacturing quality, regulatory approval, provider acceptance, and tender eligibility.

What patents protect Jadelle?

Jadelle’s original implant technology was developed through Population Council research and commercialized with industry participation. The fundamental patent estate for the implant and levonorgestrel delivery technology is old and is not expected to provide meaningful present-day exclusivity in major markets.

The commercial asset is protected more by a combination of trademarks, regulatory history, manufacturing controls, and market access than by a live global composition-of-matter patent.

Potentially relevant IP categories include:

IP category	Current commercial relevance
Levonorgestrel active ingredient	Low patent barrier because the molecule is established
Implant rod composition	Potentially relevant only for later formulations or manufacturing improvements
Drug-release technology	May protect specific formulations or processes, subject to jurisdiction and expiration
Insertion or removal tools	May have device patents, but these are separate from the core drug
Manufacturing process	Often protected through know-how and trade secrets
Jadelle trademark	Brand-identification value may remain commercially relevant
Regulatory dossier	Creates practical development costs even where patents are weak

A precise current patent-family count and expiration analysis cannot be stated from the product name alone because rights vary by jurisdiction, patent family, continuations, national phase filings, and assignment history.

Are there Paragraph IV challenges or generic-entry disputes?

There is no prominent current U.S. Paragraph IV litigation campaign centered on Jadelle. The product’s limited U.S. commercial presence and age reduce the economic incentive for a conventional ANDA challenge.

Generic or follow-on competition is more likely to arise through international regulatory pathways. Potential entrants would need to demonstrate:

Pharmaceutical equivalence or adequate clinical performance
Consistent levonorgestrel release
Sterility and biocompatibility
Mechanical integrity of the rods
Reliable insertion and removal performance
Stability through the labeled shelf life
Local regulatory compliance

For public-sector procurement, WHO prequalification or equivalent regulatory recognition can materially affect market access. This creates a practical barrier even when patent protection is weak.

What litigation and settlement agreements affect Jadelle?

No major current patent litigation or settlement agreement has been publicly identified as a principal driver of Jadelle’s global market. The commercial record is dominated by access agreements, manufacturing relationships, donor-backed procurement, and product-transfer arrangements rather than by exclusionary litigation.

The absence of major litigation does not mean entry is frictionless. Reproductive-health products can face regulatory disputes, tender challenges, product-quality investigations, supply interruptions, and trademark conflicts. Those risks are generally more important than Paragraph IV litigation for Jadelle.

How strong is the Jadelle patent estate?

Jadelle has a weak-to-moderate current patent position and a stronger practical market position than its patent position alone suggests.

Factor	Assessment
Core active ingredient protection	Weak or expired
Foundational implant patents	Old and unlikely to create broad current exclusivity
Formulation and release know-how	Potentially meaningful
Manufacturing complexity	Moderate
Regulatory and quality barrier	Moderate to high
Brand recognition in public programs	Moderate
Tender and donor access	High commercial importance
Risk of technically capable follow-on products	Moderate
Risk of rapid substitution	Limited by procurement and training cycles

The most defensible competitive assets are operational: validated production, quality control, regulatory registrations, supply reliability, and access to procurement channels.

What is the biosimilar risk for Jadelle?

Biosimilar risk is not applicable because Jadelle is a chemically synthesized small-molecule drug-device combination, not a biologic. The relevant competitive threat is generic or follow-on implant entry.

The technical development burden is higher than for an oral levonorgestrel tablet because the implant requires controlled release, biocompatibility, insertion performance, and long-term stability. That burden can deter small manufacturers even without meaningful patent protection.

What licensing and ownership arrangements shape Jadelle?

Population Council has been central to Jadelle’s development and access strategy. Bayer has been associated with commercial manufacture and distribution. The product’s availability has also depended on agreements involving international procurement organizations and donors.

Commercial rights and manufacturing arrangements have changed over time. Public disclosures indicate that access strategy has prioritized supply to developing-country markets and public-health programs rather than expansion into U.S. commercial channels. [3]

These arrangements matter financially because the product’s value depends on who controls:

Manufacturing capacity
Regulatory dossiers
Country registrations
Trademark rights
Donor procurement relationships
Technology transfer
Quality oversight

What generic launch scenarios exist for Jadelle?

Base case: stable public-sector demand

Jadelle retains a role in procurement programs because it is familiar, long-acting, and cost competitive. Revenue remains steady but modest, with growth tied to contraceptive access budgets rather than price increases.

Downside case: substitution by competing implants

Sino-implant II, Levoplant, Nexplanon, or newer devices win tenders through lower price, simpler insertion, stronger registration coverage, or improved supply reliability. Jadelle volumes decline even if the overall implant category grows.

Upside case: increased implant adoption

Government commitments to long-acting contraception and donor funding expand the category. Jadelle benefits if it remains eligible for procurement and maintains reliable supply. Volume growth offsets low unit prices.

Disruption case: manufacturing or regulatory interruption

A plant shutdown, quality issue, registration lapse, or supply interruption causes procurement agencies to shift demand to other implants. Because tenders often require predictable delivery, lost contracts may be difficult to recover quickly.

What is the geographic coverage of Jadelle?

Jadelle’s commercial footprint is concentrated in countries with public-sector contraceptive programs and donor-supported procurement. Its strongest strategic relevance is in sub-Saharan Africa and other low- and middle-income markets.

Geographic performance depends on:

National registration status
WHO or procurement eligibility
Government contraceptive guidelines
Donor funding
Local provider training
Importation and distribution rules
Competitor availability

The product’s limited U.S. retail presence means North America is not a principal revenue market. Europe and higher-income Asia are also less central than public-sector markets in Africa and other developing regions.

What revenue exposure does Jadelle create for its manufacturers?

Jadelle is unlikely to be a material revenue driver for a diversified multinational pharmaceutical company. Its economic importance is greater for a specialized reproductive-health portfolio, a contract manufacturer, or an organization managing global-health procurement.

Revenue exposure is therefore asymmetric:

For a large pharmaceutical company, Jadelle is likely a small portfolio product.
For a public-health manufacturer, it may be strategically important despite low margins.
For donors and procurement agencies, it is a budget-efficient long-acting method.
For potential entrants, the opportunity is volume-based but operationally demanding.

Standalone Jadelle revenue, gross margin, annual unit volume, and customer concentration are not publicly disclosed in a form that permits a reliable financial model.

Key Takeaways

Jadelle is a five-year, two-rod levonorgestrel implant with its main commercial exposure in global public-health procurement.
Its market is driven by donor funding, government tenders, regulatory eligibility, and manufacturing reliability.
Standalone revenue is not publicly disclosed, and the product should not be modeled as a U.S. branded pharmaceutical franchise.
Core active-ingredient and foundational technology patents are old; current commercial protection depends more on know-how, quality systems, registrations, trademarks, and procurement access.
The main competitors are Nexplanon, Sino-implant II, and other low-cost contraceptive implants.
Biosimilar risk does not apply. Generic and follow-on implant risk does.
No major current Paragraph IV litigation or patent settlement is a central Jadelle market driver.
Financial upside depends primarily on volume growth in contraceptive programs, while pricing power remains limited.
The principal downside risks are tender displacement, manufacturing interruption, regulatory lapses, and substitution by simpler or lower-cost implants.

FAQs About Jadelle Market and Financial Outlook

Is Jadelle still commercially available?

Jadelle remains relevant in international contraceptive procurement, particularly in low- and middle-income markets. Availability varies by country registration, procurement contract, and supply arrangements.

Does Jadelle have a current U.S. generic competitor?

There is no major current U.S. generic Jadelle market of commercial significance. The principal competitive activity occurs through international contraceptive implants and public-sector procurement.

Is Jadelle more profitable than Nexplanon?

Public data do not support a direct product-level margin comparison. Nexplanon has stronger branded and private-market positioning, while Jadelle competes through public-sector volume and lower procurement pricing.

Can a manufacturer launch a new levonorgestrel implant without infringing Jadelle patents?

Potentially, but the manufacturer would still face regulatory, clinical, manufacturing, quality, trademark, and procurement barriers. A freedom-to-operate analysis must be performed by jurisdiction and patent family.

What is the investment risk associated with Jadelle?

The principal risks are low pricing power, limited revenue transparency, dependence on public tenders, donor-budget volatility, manufacturing concentration, and competition from other long-acting contraceptive technologies.

References

Clinton Health Access Initiative. (2013). Implant access program: Market-shaping and contraceptive implant price reductions. CHAI.
World Health Organization. (2024). Prequalified contraceptive implants and reproductive-health products. WHO Prequalification Unit. https://extranet.who.int/prequal/
Population Council. (n.d.). Jadelle contraceptive implant and global access activities. Population Council. https://popcouncil.org/
U.S. Food and Drug Administration. (1996). Jadelle levonorgestrel implant prescribing information and NDA records. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
United Nations Population Fund. (2023). Contraceptive commodity procurement and reproductive-health supplies. UNFPA. https://www.unfpa.org/commodities-partnership-unfpa-supplies

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Clinical Trials:	8
Patent Applications:	3,936
DailyMed Link:	JADELLE at DailyMed

AI Deep Research

Questions you can ask:

Summary for JADELLE

Recent Clinical Trials for JADELLE